Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing

Nuclear Medicine and Biology

Volumn 42, Issue 6, 2015, Pages 555-560

  Johnström, Peter ^a,b   Bergman, Linda ^b   Varnäs, Katarina ^b   Malmquist, Jonas ^c   Halldin, Christer ^b   Farde, Lars ^a,b  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

AZD3241; Carbon 11; Cyanation; Microdosing; Myeloperoxidase; PET

Indexed keywords

1,2,3,5 TETRAHYDRO 1 (2 ISOPROPOXYETHYL) 2 THIOXOPYRROLO[3,2 D]PYRIMIDIN 4 ONE; CARBON 11; CARBONYL DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CHLORIDE; ENZYME INHIBITOR; ETHYL 3 (2 ISOPROPOXYETHYLAMINO) 1H PYRROLE 2 CARBOXYLATE; ISOTHIOCYANIC ACID; MYELOPEROXIDASE; POTASSIUM CYANIDE; THIOCYANATE POTASSIUM; UNCLASSIFIED DRUG; CARBON; PEROXIDASE; PYRIMIDINONE DERIVATIVE; PYRROLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; VERDIPERSTAT;

ANIMAL EXPERIMENT; ARTICLE; CYCLIZATION; DRUG DISTRIBUTION; DRUG MICRODOSE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HEATING; ISOTOPE LABELING; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MICROWAVE RADIATION; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOCHEMISTRY; REPRODUCIBILITY; STRUCTURE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; RADIATION RESPONSE; SCINTISCANNING; SYNTHESIS;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MACACA FASCICULARIS; MAGNETIC RESONANCE IMAGING; MALE; PEROXIDASE; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINONES; PYRROLES; RADIOPHARMACEUTICALS;

EID: 84928827613     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2015.02.001     Document Type: Article

References (20)

1. Van Der Veen B.S., De Winther M.P.J., Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal 2009, 11:2899-2937.
2. Bögevig A., Lo-Alfredsson Y., Pivonka D., Tidén A. Preparation of pyrrolo[3,2-d]pyrimidin-4-one derivatives as MPO enzyme inhibitors. WO 2006/062465 A1 15 June, 2006.
3. Tidén A.K., Sjögren T., Svensson M., Bernlind A., Senthilmohan R., Auchere F., et al. 2-Thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J Biol Chem 2011, 286:37578-37589.
4. Bergström M., Grahnen A., Långström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003, 59:357-366.
5. Lee C.-M., Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006, 27:310-316.
6. Wagner C.C., Langer O. Approaches using molecular imaging technology - use of PET in clinical microdose studies. Adv Drug Deliv Rev 2011, 63:539-546.
7. Halldin C., Gulyás B., Farde L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des 2001, 7:1907-1929.
8. Bolton R. Isotopic methylation. J Label Compd Radiopharm 2001, 44:701-736.
9. Malmquist J., Bernlind A., Johansson M., Juréus A., Nilsson M. Imaging agents for myeloperoxidase. J Label Compd Radiopharm 2012, 55:393-399.
10. Varrone A., Sjöholm N., Eriksson L., Gulyás B., Halldin C., Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 2009, 36:1639-1650.
11. Hong I.K., Chung S.T., Kim H.K., Kim Y.B., Son Y.D., Cho Z.H. Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction. IEEE Trans Med Imaging 2007, 26:789-803.
12. Clark J.D., Baldwin R.L., Bayne K.A., Brown M.J., Gebhart G.F., Gonder J.C., et al. Guide for the care and use of laboratory animals 1996, National Academies Press, Washington, DC.
13. 11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology 1993, 113:149-156.
14. Roland P.E., Graufelds C.J., Wåhlin J., Ingelman L., Andersson M., Ledberg A., et al. Human brain atlas: for high-resolution functional and anatomical mapping. Hum Brain Mapp 1994, 1:173-184.
15. 14C]-isothiocyanate. J Label Compd Radiopharm 2008, 51:419-421.
16. 11C]sodium thiocyanate for in vivo studies of anion kinetics using positron emission tomography (PET). Int J Rad Appl Instrum B 1989, 16:741-746.
17. Green P.S., Mendez A.J., Jacob J.S., Crowley J.R., Growdon W., Hyman B.T., et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neurochem 2004, 90:724-733.
18. Maki R.A., Tyurin V.A., Lyon R.C., Hamilton R.L., DeKosky S.T., Kagan V.E., et al. Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. J Biol Chem 2009, 284:3158-3169.
19. Breckwoldt M.O., Chen J.W., Stangenberg L., Aikawa E., Rodriguez E., Qiu S., et al. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci U S A 2008, 105:18584-18589.
20. Chen J.W., Breckwoldt M.O., Aikawa E., Chiang G., Weissleder R. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain 2008, 131:1123-1133.